Health Care Costs

"Health Care Costs" Main

Latest Morning Briefing Stories

‘Queen Of Soul’s’ Death Highlights Viciousness Of Pancreatic Cancers

KHN Morning Briefing

Pancreatic cancer is the third-leading cause of death from cancer in the United States, following lung and colorectal cancers. Meanwhile, new research from the University of California-Davis shows that Californians are faring better against most types of cancer because of early detection and more effective treatments. CNN explores one scenario that plays out when insurers won’t pay for care.

Trump Administration Value-Based Rule Expected To Force ACOs To Adapt Or Bolt

KHN Morning Briefing

The National Association of ACOs signals that the Health and Human Services plan will cause affordable care organizations to leave Medicare’s Shared Savings Program. News outlets also report on industry news surrounding a heart valve procedure that is saving lives, a Q2 drop in bankruptcies and a “tidal wave of change” predicted from Colorado companies.

First Generic Version Of EpiPen Injector Approved By FDA And Could Lower Cost Of Drug

KHN Morning Briefing

Teva gets approval from the Food and Drug Administration to sell its version of the epinephrine auto-injector, but hasn’t yet revealed its pricing. Mylan, the manufacturer of the brand-name EpiPen, has faced public criticism and congressional investigations for raising the price of its lifesaving drug 450 percent since 2004.

In Second Month Of Arkansas’ Work Requirements, Thousands Fail To Report Hours Even Though They Meet Them

KHN Morning Briefing

The beneficiaries have to log hours through other programs, so officials know that they’re meeting them and simply just not reporting them. Critics warned of this scenario before work requirements were instituted because, according to analysts, one in three Medicaid adults never use a computer or the internet and four in ten do not use email. Medicaid news comes out of Ohio, as well.

Amid Giddiness Over First-Ever Gene-Silencing Drug’s Approval Is An Acknowledgment Of Its Limitations

KHN Morning Briefing

Right now, the RNAi drug is limited to cells that go through the liver, which is — in relative terms — easy to target. Getting the drug to other tissue, like the skin or brain, is more challenging. “It’s always been the same problem. And it’s delivery, delivery, delivery,” Steven Dowdy, a cancer biologist at the University of California, San Diego’s school of medicine, tells Stat. “It’s always been the 800-pound gorilla in the room.”

First Gene-Silencing Drug Approved By FDA — And It Comes With An Eye-Popping Price Tag

KHN Morning Briefing

Slicing genes with drugs is the latest in a wave of hot new treatments geared toward fighting diseases in unique ways. But the price on innovation is steep. In other news, the FDA plans to streamline drug safety evaluations and a super PAC goes after Rep. Anna Eshoo (D-Calif.) over the money she’s taken from the pharmaceutical industry.

HHS Cracks Down On Drug Companies Taking Advantage Of Loophole In Medicaid’s Complex Payment Structure

KHN Morning Briefing

The new guidance, which officials say will cut back on the companies’ “abusive behavior,” concerns the rebates that drug makers have to pay back to states when a patient receives one of their medicines. In other pharmaceutical news: the administration is preparing to put action behind its rhetoric on drug pricing; some say Medicare’s new negotiating powers could lead to increased hospitalizations; and more.

CVS Wants Pharma To Stop Pointing Fingers At The Middlemen When It Comes To High Drug Prices

KHN Morning Briefing

“Drug manufacturers want you to believe that increasing drug prices are a result of them happy to pay rebates and that PBMs are retaining these rebates. And this is simply not true,” said Larry Merlo, the CEO of CVS, which owns Caremark, one of the biggest pharmacy-benefit managers. Meanwhile, the American Medical Association speaks out against CVS’ attempts to acquire insurer Aetna. And Rite Aid and Albertsons call off their merger.